MC2-THERAPEUTICS
7.8.2019 15:47:12 CEST | Business Wire | Press release
MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the completion of enrollment for its EU Phase 3 study assessing the safety and efficacy of MC2-01 PAD™ Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in adult patients with plaque psoriasis compared to Daivobet® gel (marketed in the US as Taclonex® Topical Suspension).
“Completion of patient enrollment in this EU Phase 3 registration study marks yet another significant and timely accomplishment for the MC2-01 PAD™ Cream global development program in plaque psoriasis following our successful US Phase 3 head-to-head study in 2018, ” stated Jesper J. Lange, CEO & President of MC2 Therapeutics. He added: “Our efforts in both EU and US demonstrate that we are committed to build leadership in topical therapies for patients with chronic inflammatory conditions. Our proprietary PAD™ Technology enables us to develop a new standard of topical therapies that combine fast and effective relief of symptoms with a unique moisturizing and cosmetic feel that we believe will significantly upgrade the patient experience and convenience in daily routines.”
About the MC2-01 PAD™ Cream Phase 3 Study
The study is a Phase 3, randomized, multicenter, investigator-blind, parallel-group study to evaluate the efficacy and safety of MC2-01 PAD™ Cream in subjects with plaque psoriasis compared to MC2-01 vehicle and Daivobet® gel. Subjects apply study medication topically once daily for up to 8 weeks. The primary objective is to show therapeutic superiority of MC2-01 PAD™ Cream to the active comparator, as well as to characterize the safety profile of MC2-01 PAD™ Cream in subjects with plaque psoriasis. The primary efficacy endpoint is percentage change from baseline in mPASI on the body at Week 8. The study enrolled 490 patients in 32 centres in Europe.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions. Using its proprietary PAD™ Technology – a unique oil-in-water dispersion – MC2 Therapeutics is developing a pipeline of novel innovative topical therapies designed for unique patient experiences.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Agrees to Acquire Central London Office Building26.2.2026 08:51:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has reached an agreement to acquire 90 Whitfield Street in London, UK from Derwent London. The property, located in central London’s West End sub-market of Fitzrovia, is comprised of 107,000 total square-feet with 99,000 square-feet dedicated to fully developed office space and a retail space on the ground floor of 8,000 square-feet. The building offers highly desirable styling including floor-to-ceiling glazing and generous heights, flexible floor plates, a recently refurbished reception space and large central atrium, and the property’s top floor includes its own privately accessed 900 square-foot rooftop terrace. The asset is also located on an attractive corner position that affronts Tottenham Court Road, one of London’s principal thoroughfares, and is within walking distance of six separate tube stations providing access from across the greater metropolitan area. “We have strong
INNIO signs Definitive Agreement to Acquire Enerflex APAC Operations, Expanding Service Capabilities in the Asia-Pacific Region26.2.2026 07:34:00 CET | Press release
INNIO Group, a leading energy solution and service provider, today announced it has signed a definitive agreement with Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) to acquire their aftermarket business operations in Australia, Thailand and Indonesia. The transaction advances INNIO’s strategy to strengthen its presence in the Asia-Pacific (APAC) region and enhance customer proximity. The transaction is subject to customary closing conditions and regulatory approvals. Closing is expected during the second half of 2026. The Enerflex APAC aftermarket business operates principally in three countries and eight locations. The company offers extensive workshop and office space, as well as a strong installed base. This base is supported by long-term service agreements with major oil and gas companies. Dr. Dennis Schulze, CFO of INNIO Group, commented: “By integrating Enerflex’s expertise in the APAC region, we strengthen our service portfolio, deliver greater customer value, and accelerate growth in A
Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle26.2.2026 07:16:00 CET | Press release
12M 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225107874/en/ Oliver Bäte, Chief Executive Officer of Allianz SEExcellent momentum and record operating profitTotal business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever Shareholders’ core net income advances 10.9 percent to 11.1 billion euros Core earnings per share (EPS) grow 12.5 percent and reach 28.61 euros Core return on equity (RoE) reaches an excellent level of 18.1 percent Solvency IIratio2 increases 10 percentage points to 218 percent supported by excellent capital generation 4Q 2025 Diversified growth and double-digit increase in shareholders’ core net incomeTotal business volume rises 6.5 1 percent with contributions from all segments Operating profit increases 3.0 percent to 4.3 billion euros, driven by excelle
Tigo Energy Showcases Real-time Active Commissioning Software at KEY 2026 Expo26.2.2026 06:00:00 CET | Press release
Next-generation commissioning system designed to help streamline solar installations delivers another Total Quality Solar innovation as Tigo expands installer loyalty program Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo,” “Company”), a leading provider of intelligent solar and energy software solutions, today announced the Company’s presence as an exhibitor at the 2026 KEY – The Energy Transition Expo in Rimini, Italy, where Tigo will preview the new active commissioning software. From basic solar-only installations to advanced solar-plus-storage configurations, the system supports installers throughout the entire jobsite workflow via the Tigo EI App, delivering on-site guidance, real-time progress visibility, and clear verification of every required step to help reduce delays, truck rolls, and commissioning uncertainty. At KEY 2026, Tigo will also showcase the latest expansions to the Installer Loyalty Program, including new eligibility tiers and segments, enhanced data support for install
Indra Group Exceeds All Its Guidances in 2025 and Sets Even More Ambitious Guidances for 2026 Than Those Set Out in Its 'Leading the Future' Strategic Plan25.2.2026 23:08:00 CET | Press release
Results in fiscal year 2025Revenues increased by 13%, totaling €5.457 billion in 2025Indra Group sets financial guidances at least 17% higher than those foreseen in its Strategic Plan for 2026Indra Group announces thepayment of a €0.30 dividend per share (more than 20% above the dividend in 2024) charged to the earnings posted in 2025The results and the increase in the order intake confirm Indra Group’s industrial strength and its capacity to tackle and execute the major defence modernization programs Indra Group (MAD:IDR): • The fourth-quarter order intake in 2025 totaled €8.329 billion, raising thefull-year backlog to €16.083 billion (122% more than in 2024). The Defence backlog stood at €11.336 billion, far exceeding the target of more than €10 billion set for 2026. • Revenues increased by 13% in 2025 with respect to 2024, with double-digit year-on-year rises in Defence, ATM and Mobility Revenues recorded a 28% year-on-year rise in the final quarter of the year • EBITDA and EBIT rec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom